NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN), a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need, today reported its financial and operational results for the three and six months ended June 30, 2016.
“Kadmon has achieved several key clinical and corporate milestones in 2016, including the recent successful completion of our initial public offering,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “As we continue to rapidly advance our pipeline, we have strengthened operational efficiency and cost-saving measures within the Company to prioritize data delivery from our ongoing and planned clinical studies.”
“Kadmon has achieved several key clinical and corporate milestones in 2016, including the recent successful completion of our initial public offering,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “As we continue to rapidly advance our pipeline, we have strengthened operational efficiency and cost-saving measures within the Company to prioritize data delivery from our ongoing and planned clinical studies.”
